Christine Baeder, chief operating officer for generics and biosimilars at Teva USA and newly named chair of the Association for Accessible Medicines, tells this week’s Video Forum about the threats facing the generic pharmaceutical industry and what should be done to counter them. She also discusses the relatively slow pace of adoption of biosimilars in
NEW YORK — FDA-approved generic and biosimilar medicines are key to America’s health care, filling nine out of ten prescriptions dispensed in the United States. Dan Leonard, president and CEO of the Association for Accessible Medicines (AAM), recently partnered with YourUpdate TV on a nationwide media tour to discuss why reliable, affordable, high-quality prescription medication
Dan Leonard, longtime leader of the National Pharmaceutical Council who became CEO of the Association for Accessible Medicines in September, discusses the impact of generic medications on health care, and the challenges and opportunities facing the industry. Among the issues addressed are generics’ role in treating COVID-19 patients, the emergence of biosimilars, and the Medicaid
WASHINGTON — Prescription abandonment is sharply higher for branded drugs than generic drugs, a new annual report commissioned by the Association for Accessible Medicines (AAM) found. AAM said Monday that abandonment — defined as the failure to pick up a new script — was nearly three times as high for brand-name drugs as for generics